FF, the fibrates class of lipid-lowering drugs, is commonly used in the treatment of HLD as a PPARα agonist for reducing cardiovascular risks and treating NAFLD/nonalcoholic steatohepatitis [46, 47], as well as improving the GLU tolerance and lowering adiposity [48]. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.